



## Advancements in Antipsychotics

Guest Editor:

**Dr. Kyle Burghardt**

Department of Pharmacy  
Practice, Wayne State University,  
Detroit, MI 48201, USA

Deadline for manuscript  
submissions:

**closed (30 June 2024)**

### Message from the Guest Editor

Dear Colleagues,

Antipsychotic medications are the primary pharmacotherapeutic option used in the treatment of severe mental illness, including schizophrenia and bipolar disorder; however, their use is expanding to several other populations and disease states. Antipsychotics, while efficacious, exhibit a high degree of interindividual effectiveness as well as side effects leading to non-adherence. The exact mechanisms underlying the heterogeneous response to antipsychotic treatment remain to be fully elucidated. The aim of this Special Issue is to collect and publish findings on recent advancements in antipsychotic research. This Special Issue is especially focused on omic-type studies of antipsychotic treatment outcomes but can also include imaging studies, other mechanism-type studies or adjunct treatment studies. Submissions can include original research or review articles.

Dr. Kyle Burghardt  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](https://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
X@Biomed\_MDPI